The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

Who Took Part

The study group was 2 patients.

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

In the crossover set-up each of the patients took both Insulin Aspart and the comparison in turn, acting as their own control.

Main PD/PK outcome parameters measured were early- and late-phase glucose disposal (area under the curve of glucose infusion rate [AUC(GIR)]), nonesterified fatty acid concentrations, and IAsp concentrations.

What Was Measured

The subject headings attached to it are Area Under Curve, Biphasic Insulins, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Fasting and Fatty Acids, Nonesterified.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Insulin Aspart compound page.